Fig. 6From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trialsComparison of MHDs reduction between 120 mg and 240 mg galcanezumab. WMD weighted mean differencesBack to article page